Mirikizumab vs standard treatment for newly diagnosed ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with ulcerative colitis within the last 12 months.
- Your disease is moderate to severe and has not responded well enough to 5-ASA medications (like mesalamine) or steroids.
- You have never taken azathioprine, 6-MP, or advanced therapies (biologics or JAK inhibitors) before.
- You are willing to undergo colonoscopies and fill out a daily diary.
- You do not have Crohn's disease, active infections like hepatitis or tuberculosis, or a history of cancer (except non-melanoma skin cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This trial tests a medication called Mirikizumab for adults over 60 with moderate to severe Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective for older adults with these conditions.
This study is testing if a special ultrasound method (called Modified Milan Ultrasound Criteria) can accurately measure how active and severe your ulcerative colitis is. It is for people with moderate-to-severe UC who are starting a new treatment called mirikizumab.
This trial tests whether starting with a powerful biologic drug (mirikizumab) works better than the usual first treatment (azathioprine) for people who have just been diagnosed with moderate-to-severe Crohn's disease and haven't tried stronger medications yet.
This study follows people with ulcerative colitis who are starting or have just started mirikizumab treatment. It aims to understand how well the drug works in real-world settings and how patients do over the next 12 months.
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.